Tagged: Fast Track

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Oncoprex in combination with Tagrisso received fast track designation from the Food and Drug Administration to treat patients with non-small cell lung cancer.

Read More

FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC

The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib (Tagrisso) for the treatment of patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after treatment with osimertinib alone, according to a press release from Genprex, Inc, developer of the therapeutic.

Read More